Ask AI

From Biomarker to Bedside: B7-H3–Directed ADCs in the Evolving Extensive-Stage Small-Cell Lung Cancer Treatment Landscape

Enhance your knowledge of the emerging efficacy and safety data with B7-H3–directed ADCs and strategies to individualize treatment in extensive-stage small-cell lung cancer, including patient-specific factors that influence treatment selection and sequencing through a podcast, certified video modules with accompanying downloadable slides, and an expert-authored commentary.

Share

Program Content

Activities

Targeting B7 H3 in ES SCLC
Evolving Role of B7-H3–Directed ADCs in the Extensive-Stage Small-Cell Lung Cancer Treatment Landscape
Podcast
Congratulations: You achieved a completion on 04/09/2022

Released: September 10, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Supporters

This activity is supported by educational grants from Daiichi Sankyo, Inc. and Merck Sharp & Dohme LLC.

Daiichi Sankyo, Inc.

Merck Sharp & Dohme LLC